Compare Tesla, Inc. (TSLA) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tesla, Inc. vs Zimmer Biomet Holdings Inc — how do they compare? Tesla, Inc. trades at $384.4 (market cap $1.48T), while Zimmer Biomet Holdings Inc trades at $88.96 (market cap $16.95B). The key difference: Tesla, Inc. is far larger — about 87.3× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tesla, Inc. for 88 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| TSLA | ZBH | |
|---|---|---|
Market Cap | $1.48T | $16.95B |
Volume | 28,215,427 | 2,505,240 |
Sector | Consumer Cyclical | Health |
52-Week High | $489.88 | $103.98 |
52-Week Low | $298.16 | $79.58 |
Typical Hold Time | 88 Days | 89 Days |
Enterprise Value | $1.45T | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tesla (TSLA) trades at $377.61, down 0.81% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported mixed Q2 2026 earnings, missing EPS estimates, while revenue has softened slightly in 2025. Analyst consensus remains positive with a $441.36 price target, and recent news highlights regulatory approval for self-driving software in Europe and a potential cheaper EV launch.
Tesla's outlook balances innovation in autonomy and energy against near-term earnings pressure and high valuations. Investment opportunities lie in AI and robotaxi growth, but risks include intense EV competition, execution on new technologies, and profitability concerns given a P/E of 347.22. The stock's performance hinges on delivering future growth to justify its premium valuation.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
